Casi Pharmaceuticals Stock Total Debt
| CASI Stock | USD 2.33 0.03 1.27% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess CASI Pharmaceuticals' long-term financial health and intrinsic value.
The CASI Pharmaceuticals' current Total Debt To Capitalization is estimated to increase to 0.97. CASI | Total Debt | Build AI portfolio with CASI Stock |
CASI Pharmaceuticals Company Total Debt Analysis
CASI Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current CASI Pharmaceuticals Total Debt | 22.14 M |
Most of CASI Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CASI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CASI Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for CASI Pharmaceuticals is extremely important. It helps to project a fair market value of CASI Stock properly, considering its historical fundamentals such as Total Debt. Since CASI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CASI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CASI Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
CASI Total Debt Historical Pattern
Today, most investors in CASI Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CASI Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CASI Pharmaceuticals total debt as a starting point in their analysis.
CASI Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
CASI Net Debt
Net Debt |
|
Based on the latest financial disclosure, CASI Pharmaceuticals has a Total Debt of 22.14 M. This is 99.2% lower than that of the Biotechnology sector and 93.18% lower than that of the Health Care industry. The total debt for all United States stocks is 99.58% higher than that of the company.
CASI Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CASI Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CASI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing CASI Pharmaceuticals by comparing valuation metrics of similar companies.CASI Pharmaceuticals is currently under evaluation in total debt category among its peers.
CASI Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CASI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CASI Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
CASI Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in CASI Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CASI Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CASI Pharmaceuticals' value.| Shares | Ubs Group Ag | 2025-03-31 | 3.1 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.5 K | Wells Fargo & Co | 2025-03-31 | 505 | Blackrock Inc | 2025-03-31 | 296 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 134 | Simplex Trading, Llc | 2025-03-31 | 114 | Bank Of America Corp | 2025-03-31 | 66.0 | Jpmorgan Chase & Co | 2025-03-31 | 25.0 | Citigroup Inc | 2025-06-30 | 19.0 | Vr Adviser, Llc | 2025-06-30 | 987.3 K | Foresite Capital Management Vi Llc | 2025-06-30 | 787.1 K |
CASI Fundamentals
| Return On Equity | -10.94 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.49) % | ||||
| Operating Margin | (2.57) % | ||||
| Current Valuation | 48.53 M | ||||
| Shares Outstanding | 15.49 M | ||||
| Shares Owned By Insiders | 48.38 % | ||||
| Shares Owned By Institutions | 20.42 % | ||||
| Number Of Shares Shorted | 342.32 K | ||||
| Price To Earning | (16.46) X | ||||
| Price To Book | 11.21 X | ||||
| Price To Sales | 1.16 X | ||||
| Revenue | 28.54 M | ||||
| Gross Profit | 12.95 M | ||||
| EBITDA | (34.87 M) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 24.57 M | ||||
| Cash Per Share | 1.81 X | ||||
| Total Debt | 22.14 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | (1.31) X | ||||
| Cash Flow From Operations | (29.22 M) | ||||
| Short Ratio | 0.10 X | ||||
| Earnings Per Share | (2.89) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 233 | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 36.56 M | ||||
| Total Asset | 53.67 M | ||||
| Retained Earnings | (700.08 M) | ||||
| Working Capital | 3.12 M | ||||
| Current Asset | 17.15 M | ||||
| Current Liabilities | 3.51 M | ||||
| Net Asset | 53.67 M |
About CASI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CASI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CASI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CASI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| NOAH | Noah Holdings | |
| CIG | Companhia Energetica de | |
| BBVA | Banco Bilbao Viscaya | |
| ENIC | Enel Chile SA | |
| SBSW | Sibanye Gold Ltd |
Check out CASI Pharmaceuticals Piotroski F Score and CASI Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.89) | Revenue Per Share | Quarterly Revenue Growth 0.049 | Return On Assets | Return On Equity |
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.